Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00735475 · ClinicalTrials.gov registry record · Phase 4
A Study to Determine the Immunogenicity and Safety Profile of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Comparator Influenza Virus Vaccine
A Phase 4 study, sponsored by Seqirus.
- Completed
- Registry status
- Phase 4
- Development phase
- 1,268
- Enrollment target
NCT00735475 is a Phase 4 study that has completed, run by Seqirus. The registered enrollment target is 1,268 participants.
The verdict
NCT00735475, a Phase 4 study, has completed, sponsored by Seqirus.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 1,268 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the immunogenicity and safety profile of CSL Limited's Influenza Virus Vaccine compared to a US Licensed Comparator Influenza Virus Vaccine.
Interventions
- BIOLOGICAL CSL Limited Influenza Virus Vaccine (Afluria®)
- BIOLOGICAL US Licensed Influenza Virus Vaccine (Fluzone®)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,268 participants |
| Start Date | 2008-10 |
| Est. Completion | 2009-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00735475
The ClinicalTrials.gov registry entry for NCT00735475 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 1,268 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seqirus, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which CSL Limited Influenza Virus Vaccine (Afluria®) is the first listed.
NCT00735475 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00735475 about?
NCT00735475 is a clinical study titled "A Study to Determine the Immunogenicity and Safety Profile of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Comparator Influenza Virus Vaccine". The purpose of this study is to determine the immunogenicity and safety profile of CSL Limited's Influenza Virus Vaccine compared to a US Licensed Comparator Influenza Virus Vaccine.
What is the current status of trial NCT00735475?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 1,268 participants. The study started on 2008-10. Estimated completion is 2009-06.
What interventions are being tested in trial NCT00735475?
The interventions under investigation include: CSL Limited Influenza Virus Vaccine (Afluria®) (BIOLOGICAL), US Licensed Influenza Virus Vaccine (Fluzone®) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00735475?
This trial is sponsored by Seqirus, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.